Status:
COMPLETED
Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults
Lead Sponsor:
Pfizer
Conditions:
Healthy Participants
Healthy Subjects
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults, following single dose administration.
Eligibility Criteria
Inclusion
- 18 years or older and overtly healthy
- Body mass Index (BMI) between 16-32 kg/m2; and a total body weight \>50 kg (110 lb)
Exclusion
- Evidence or history of clinically significant medical conditions or laboratory abnormality
- Any condition possibly affecting drug absorption
- Known intolerance/hypersensitivity to a GLP-1 R agonist
- Use of prescription drugs, nonprescription drugs, dietary supplements or herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of danuglipron in each part of the study.
Key Trial Info
Start Date :
November 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT06153758
Start Date
November 27 2023
End Date
September 30 2024
Last Update
October 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Anaheim Clinical Trials, LLC
Anaheim, California, United States, 92801